Good day, and welcome to the XWELL, Inc. Third Quarter 2024 Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] I would now like to turn the conference over to Suzanne Scrabis, Chief Financial Officer. Please go ahead, ma’am.

Good day, everyone. Welcome to XWELL’s conference call to review our third quarter 2024 financial results. Joining me on today’s call is Ezra Ernst, XWELL’s Chief Executive Officer. We have posted our fiscal year earnings release on the Investor Relations section of our website located at www.xwell.com. A link to the webcast of today’s conference call can also be found on our site. Before turning the call over to Ezra for his prepared remarks, we need to advise you of the following. Comments made on today’s call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on current assumptions as of the date of this earnings conference call and webcast and opinions that involve a variety of known and unknown risks and uncertainties. Actual results may differ materially from those contained in or suggested by such forward-looking statements. Important factors that might cause such differences include those set forth from time to time in our SEC filings, including our annual report on Form 10-K for the year ended December 31, 2023, as well as our other current and periodic reports that we file with the SEC. With that said, I’d now like to turn the call over to Ezra.

Thank you so much, Suzanne. I want to thank everyone who’s joining us on the call today and also express our appreciation for your continued interest in XWELL. As this is my first earnings call as the company’s CEO, I’d like to give you a brief overview of my 25-plus year career. For those of you who may not know me, I’ve been with XWELL for several years, having first served as CEO of our HyperPointe brand beginning in March of 2020 and CEO of XpresCheck brand since January of 2022. Operationally, during this time, I led the collaboration with the Center for Disease Control and Prevention under which we helped establish the CDC’s Traveler-based Genomic Surveillance program. Initially, it was a small pilot. It was built on XpresCheck’s advanced COVID-19 testing capabilities and HyperPointe’s marketing expertise. Over time we evolved the program into a key component of the United States’ biosecurity infrastructure, and we continue to be very proud of the important work we are doing with our partners and the CDC. Prior to joining XWELL, I held multiple senior management positions, including CEO of Physician’s Weekly, Chief Commercial Officer of Treato, General Manager at WebMD, and President at OptumHealth Education, a UnitedHealthcare company, as well as a few others. With that color in mid-September, I was excited to take on the expanded role as sole Chief Executive Officer for XWELL. The transition from Scott has been very smooth and I’m pleased with XWELL’s continued momentum. From my perspective, by consolidating our dual CEO operating structure, we successfully realigned resources while creating a leaner, more agile decision-making structure. This streamlined approach also aligns with our broader cost reduction strategy and supports our efforts to return the company to profitability. At the same time, it advances the Board of Directors’…

Thank you, Ezra. I'm now going to provide a brief synopsis of our third quarter results. However, for details, please refer to the 10-Q filed with the SEC. For the quarter, total revenue was approximately $8.4 million compared to $7.5 million in the prior year period. Third quarter 2024 revenue primarily consisted of approximately $4.9 million from XpresSpa locations and Treat locations; approximately $3.1 million from XpresTest, which includes XWELL's biosurveillance partnership and its HyperPointe business; and approximately $0.4 million from Naples Wax Center, which was acquired near the end of the 2023 third quarter. Turning to expenses. Salaries and benefits were approximately $1.9 million in the third quarter of 2024 compared to $1.2 million in the same period in 2023. It's important to note that our 2023 third quarter included approximately $1 million from a non-recurring Employee Retention Credit or ERC, which helped reduce salary and benefit costs last year. If you exclude the non-recurring ERC credit, our 2024 third quarter salaries and benefits would have decreased 4% year-over-year. Our general and administrative expenses were approximately $4.5 million, including over $2 million related to extraordinary legal expenses compared to approximately $3 million for the 2023 third quarter. Total operating expenses were approximately $6.8 million compared to approximately $13.2 million for the 2023 third quarter. We reported an operating loss for the third quarter of $4.8 million compared to an operating loss of $12.1 million in the prior year third quarter. Our net loss attributable to common shareholders was $4.8 million compared to $11.5 million in the prior year same period. Turning to our balance sheet. Our liquidity remains solid. Our cash and cash equivalents totaled $4.4 million, and we had $11.7 million in marketable securities. Our total current assets were approximately $19.5 million, and we have no long-term debt. Looking ahead, we remain focused on continued improvements in execution, including prudent cost management and enhanced operational processes. That concludes my remarks, and thanks again for joining our call today. Both Ezra and I look forward to speaking with you again in the months ahead. I'll now turn the call back to the operator.

Thank you. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.